{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T08:11:17Z","timestamp":1793434277228,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:00:00Z","timestamp":1667174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:00:00Z","timestamp":1667174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol. Res. Pract."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Seizure Related 6 Homolog Like 2 (SEZ6L2) protein\u00a0has been shown to have implications in neuronal and especially motor function development. In oncology, overexpression of SEZ6L2 serves as a negative prognostic marker in several tumor entities. Recently, few cases of anti-SEZ6L2 antibody mediated cerebellar syndromes were reported. In this article, we present a case of a 70-year-old woman with subacute onset of gait disturbance, dysarthria and limb ataxia. Serum anti-SEZ6L2 antibodies were markedly increased, and further diagnostic workup revealed left sided breast cancer. Neurological symptoms and SEZ6L2 titer significantly improved after curative tumor therapy. This is a very rare and educationally important report of anti-SEZ6L2 autoimmune cerebellar syndrome with a paraneoplastic etiology. Additionally, we performed a review of the current literature for SEZ6L2, focusing on comparing the published cases on autoimmune cerebellar syndrome.<\/jats:p>","DOI":"10.1186\/s42466-022-00218-4","type":"journal-article","created":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T01:02:19Z","timestamp":1667178139000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Anti-SEZ6L2 antibodies in paraneoplastic cerebellar syndrome: case report and review of the literature"],"prefix":"10.1186","volume":"4","author":[{"given":"Annika","family":"Kather","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Holtbernd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Brunkhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimah","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Markewitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus-Peter","family":"Wandinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Wiesmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg B.","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone C.","family":"Tauber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,31]]},"reference":[{"key":"218_CR1","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1136\/practneurol-2020-002567","volume":"21","author":"CE Uy","year":"2021","unstructured":"Uy, C. E., Binks, S., & Irani, S. R. (2021). Autoimmune encephalitis: Clinical spectrum and management. Practical Neurology, 21, 412\u2013423.","journal-title":"Practical Neurology"},{"key":"218_CR2","doi-asserted-by":"publisher","first-page":"e1088","DOI":"10.1212\/NXI.0000000000001088","volume":"8","author":"FS Thaler","year":"2021","unstructured":"Thaler, F. S., et al. (2021). Rituximab treatment and long-term outcome of patients with autoimmune encephalitis: Real-world evidence from the GENERATE Registry. Neurology Neuroimmunology Neuroinflammation, 8, e1088.","journal-title":"Neurology Neuroimmunology Neuroinflammation"},{"key":"218_CR3","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1001\/jamaneurol.2021.3188","volume":"78","author":"M Nosadini","year":"2021","unstructured":"Nosadini, M., et al. (2021). Use and safety of immunotherapeutic management of N-methyl-d-aspartate receptor antibody encephalitis: A meta-analysis. JAMA Neurology, 78, 1333\u20131344.","journal-title":"JAMA Neurology"},{"key":"218_CR4","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/0169-328X(94)00203-Q","volume":"28","author":"K Shimizu-Nishikawa","year":"1995","unstructured":"Shimizu-Nishikawa, K., Kajiwara, K., Kimura, M., Katsuki, M., & Sugaya, E. (1995). Cloning and expression of SEZ-6, a brain-specific and seizure-related cDNA. Molecular Brain Research, 28, 201\u2013210.","journal-title":"Molecular Brain Research"},{"key":"218_CR5","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1007\/s00415-018-8785-z","volume":"265","author":"H Yaguchi","year":"2018","unstructured":"Yaguchi, H., et al. (2018). Anti-Sez6l2 antibody detected in a patient with immune-mediated cerebellar ataxia inhibits complex formation of GluR1 and Sez6l2. Journal of Neurology, 265, 962\u2013965.","journal-title":"Journal of Neurology"},{"key":"218_CR6","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.bbrc.2017.10.047","volume":"494","author":"H Yaguchi","year":"2017","unstructured":"Yaguchi, H., et al. (2017). Sez6l2 regulates phosphorylation of ADD and neuritogenesis. Biochemical and Biophysical Research Communications, 494, 234\u2013241.","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"218_CR7","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1242\/jcs.179374","volume":"129","author":"M Boonen","year":"2016","unstructured":"Boonen, M., et al. (2016). Cathepsin D and its newly identified transport receptor SEZ6L2 can modulate neurite outgrowth. Journal of Cell Science, 129, 557\u2013568.","journal-title":"Journal of Cell Science"},{"key":"218_CR8","doi-asserted-by":"publisher","first-page":"e17289","DOI":"10.1371\/journal.pone.0017289","volume":"6","author":"M Konyukh","year":"2011","unstructured":"Konyukh, M., et al. (2011). Variations of the candidate SEZ6L2 gene on Chromosome 16p11.2 in patients with autism spectrum disorders and in human populations. PLoS ONE, 6, e17289.","journal-title":"PLoS ONE"},{"key":"218_CR9","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.jpsychires.2013.07.021","volume":"47","author":"G Maccarrone","year":"2013","unstructured":"Maccarrone, G., et al. (2013). Psychiatric patient stratification using biosignatures based on cerebrospinal fluid protein expression clusters. Journal of Psychiatric Research, 47, 1572\u20131580.","journal-title":"Journal of Psychiatric Research"},{"key":"218_CR10","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/j.1349-7006.2006.00258.x","volume":"97","author":"N Ishikawa","year":"2006","unstructured":"Ishikawa, N., et al. (2006). Characterization of SEZ6L2 cell-surface protein as a novel prognostic marker for lung cancer. Cancer Science, 97, 737\u2013745.","journal-title":"Cancer Science"},{"key":"218_CR11","doi-asserted-by":"publisher","first-page":"113194","DOI":"10.1016\/j.yexcr.2022.113194","volume":"417","author":"L Chen","year":"2022","unstructured":"Chen, L., Han, S., Li, Y., Zheng, Y., & Zhang, Q. (2022). SEZ6L2, regulated by USF1, accelerates the growth and metastasis of breast cancer. Experimental Cell Research, 417, 113194.","journal-title":"Experimental Cell Research"},{"key":"218_CR12","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3390\/biomedicines10020317","volume":"10","author":"Z Yu","year":"2022","unstructured":"Yu, Z., Du, M., & Lu, L. (2022). A novel 16-genes signature scoring system as prognostic model to evaluate survival risk in patients with glioblastoma. Biomedicines, 10, 317.","journal-title":"Biomedicines"},{"key":"218_CR13","doi-asserted-by":"publisher","first-page":"6768","DOI":"10.21037\/tcr-20-1527","volume":"9","author":"Z Wang","year":"2020","unstructured":"Wang, Z., et al. (2020). Overexpression of SEZ6L2 predicts poor prognosis in patients with cholangiocarcinoma. Translational Cancer Research, 9, 6768\u20136779.","journal-title":"Translational Cancer Research"},{"key":"218_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12014-018-9215-z","volume":"15","author":"J Dufresne","year":"2018","unstructured":"Dufresne, J., et al. (2018). The plasma peptides of ovarian cancer. Clinical Proteomics, 15, 41.","journal-title":"Clinical Proteomics"},{"key":"218_CR15","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3390\/biomedicines8110500","volume":"8","author":"J-S Lee","year":"2020","unstructured":"Lee, J.-S., et al. (2020). SEZ6L2 is an important regulator of drug-resistant cells and tumor spheroid cells in lung adenocarcinoma. Biomedicines, 8, 500.","journal-title":"Biomedicines"},{"key":"218_CR16","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s00415-013-7134-5","volume":"261","author":"H Yaguchi","year":"2014","unstructured":"Yaguchi, H., et al. (2014). Identification of anti-Sez6l2 antibody in a patient with cerebellar ataxia and retinopathy. Journal of Neurology, 261, 224\u2013226.","journal-title":"Journal of Neurology"},{"key":"218_CR17","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1007\/s00415-018-9115-1","volume":"266","author":"M Borsche","year":"2019","unstructured":"Borsche, M., et al. (2019). Sez6l2-antibody-associated progressive cerebellar ataxia: A differential diagnosis of atypical parkinsonism. Journal of Neurology, 266, 522\u2013524.","journal-title":"Journal of Neurology"},{"key":"218_CR18","doi-asserted-by":"publisher","first-page":"e916","DOI":"10.1212\/NXI.0000000000000916","volume":"8","author":"J Landa","year":"2021","unstructured":"Landa, J., et al. (2021). Seizure-related 6 homolog like 2 autoimmunity: Neurologic syndrome and antibody effects. Neurology-Neuroimmunology Neuroinflammation, 8, e916.","journal-title":"Neurology-Neuroimmunology Neuroinflammation"},{"key":"218_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-022-06244-z","author":"D Reis Carneiro","year":"2022","unstructured":"Reis Carneiro, D., Maresch, \u00c2., Cunha, R., & Morgadinho, A. (2022). Sez6l2-associated encephalitis in a patient with small-cell lung cancer. Neurological sciences: Official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. https:\/\/doi.org\/10.1007\/s10072-022-06244-z","journal-title":"Neurological sciences: Official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology"},{"key":"218_CR20","doi-asserted-by":"publisher","first-page":"e1131","DOI":"10.1212\/NXI.0000000000001131","volume":"9","author":"A Mehdiyeva","year":"2022","unstructured":"Mehdiyeva, A., Hietaharju, A., & Sipil\u00e4, J. (2022). SEZ6L2 antibody-associated cerebellar ataxia responsive to sequential immunotherapy. Neurology-Neuroimmunology Neuroinflammation, 9, e1131.","journal-title":"Neurology-Neuroimmunology Neuroinflammation"},{"issue":"30","key":"218_CR21","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1093\/cercor\/bhz230","volume":"1991","author":"A Nash","year":"2020","unstructured":"Nash, A., et al. (2020). Lack of Sez6 family proteins impairs motor functions, short-term memory, and cognitive flexibility and alters dendritic spine properties. Cerebral Cortex, 1991(30), 2167\u20132184.","journal-title":"Cerebral Cortex"},{"key":"218_CR22","doi-asserted-by":"publisher","first-page":"8034","DOI":"10.3390\/ijms22158034","volume":"22","author":"E Torretta","year":"2021","unstructured":"Torretta, E., et al. (2021). Novel insight in idiopathic normal pressure hydrocephalus (iNPH) biomarker discovery in CSF. International Journal of Molecular Sciences, 22, 8034.","journal-title":"International Journal of Molecular Sciences"},{"key":"218_CR23","first-page":"9515571","volume":"2022","author":"N Wang","year":"2022","unstructured":"Wang, N., et al. (2022). Identification of SMIM1 and SEZ6L2 as potential biomarkers for genes associated with intervertebral disc degeneration in pyroptosis. Disease Markers, 2022, 9515571.","journal-title":"Disease Markers"},{"key":"218_CR24","doi-asserted-by":"publisher","first-page":"e4582","DOI":"10.1371\/journal.pone.0004582","volume":"4","author":"RA Kumar","year":"2009","unstructured":"Kumar, R. A., et al. (2009). Association and mutation analyses of 16p11.2 autism candidate genes. PLoS ONE, 4, e4582.","journal-title":"PLoS ONE"},{"key":"218_CR25","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/jnr.21103","volume":"85","author":"Z-L Yu","year":"2007","unstructured":"Yu, Z.-L., et al. (2007). Febrile seizures are associated with mutation of seizure-related (SEZ) 6, a brain-specific gene. Journal of Neuroscience Research, 85, 166\u2013172.","journal-title":"Journal of Neuroscience Research"},{"key":"218_CR26","doi-asserted-by":"publisher","first-page":"917565","DOI":"10.1155\/2011\/917565","volume":"2011","author":"JC Mulley","year":"2011","unstructured":"Mulley, J. C., et al. (2011). The role of seizure-related SEZ6 as a susceptibility gene in febrile seizures. Neurology Research International, 2011, 917565.","journal-title":"Neurology Research International"},{"key":"218_CR27","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1038\/ejhg.2015.218","volume":"24","author":"A Ambalavanan","year":"2016","unstructured":"Ambalavanan, A., et al. (2016). De novo variants in sporadic cases of childhood onset schizophrenia. European Journal of Human Genetics EJHG, 24, 944\u2013948.","journal-title":"European Journal of Human Genetics EJHG"},{"key":"218_CR28","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.1111\/jcmm.15082","volume":"24","author":"N An","year":"2020","unstructured":"An, N., et al. (2020). SEZ6L2 knockdown impairs tumour growth by promoting caspase-dependent apoptosis in colorectal cancer. Journal of Cellular and Molecular Medicine, 24, 4223\u20134232.","journal-title":"Journal of Cellular and Molecular Medicine"},{"key":"218_CR29","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1080\/15257770.2021.1975298","volume":"40","author":"J Lu","year":"2021","unstructured":"Lu, J., & Chen, Q. (2021). Transcriptome-based identification of molecular markers related to the development and prognosis of Colon cancer. Nucleosides, Nucleotides & Nucleic Acids, 40, 1114\u20131124.","journal-title":"Nucleosides, Nucleotides & Nucleic Acids"},{"key":"218_CR30","doi-asserted-by":"publisher","first-page":"412","DOI":"10.21037\/gs-22-37","volume":"11","author":"X Luo","year":"2022","unstructured":"Luo, X., et al. (2022). High expression of SEZ6L2 as an independent prognostic Indicator in thyroid carcinoma. Gland Surgery, 11, 412\u2013425.","journal-title":"Gland Surgery"},{"key":"218_CR31","doi-asserted-by":"publisher","first-page":"7318703","DOI":"10.1155\/2020\/7318703","volume":"2020","author":"L Wang","year":"2020","unstructured":"Wang, L., et al. (2020). Upregulated seizure-related 6 homolog-like 2 is a prognostic predictor of hepatocellular carcinoma. Disease Markers, 2020, 7318703.","journal-title":"Disease Markers"},{"key":"218_CR32","doi-asserted-by":"publisher","first-page":"901","DOI":"10.3892\/mmr.2017.6635","volume":"16","author":"Q Wang","year":"2017","unstructured":"Wang, Q. (2017). CpG methylation patterns are associated with gene expression variation in osteosarcoma. Molecular Medicine Reports, 16, 901\u2013907.","journal-title":"Molecular Medicine Reports"},{"key":"218_CR33","doi-asserted-by":"publisher","first-page":"607641","DOI":"10.3389\/fimmu.2021.607641","volume":"12","author":"WQ Qiu","year":"2021","unstructured":"Qiu, W. Q., et al. (2021). The Sez6 family inhibits complement by facilitating factor I cleavage of C3b and accelerating the decay of C3 convertases. Frontiers in Immunology, 12, 607641.","journal-title":"Frontiers in Immunology"},{"key":"218_CR34","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s00125-011-2295-1","volume":"55","author":"J Hald","year":"2012","unstructured":"Hald, J., et al. (2012). Pancreatic islet and progenitor cell surface markers with cell sorting potential. Diabetologia, 55, 154\u2013165.","journal-title":"Diabetologia"},{"key":"218_CR35","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1001\/jamaneurol.2021.0249","volume":"78","author":"R Velasco","year":"2021","unstructured":"Velasco, R., et al. (2021). Encephalitis induced by immune checkpoint inhibitors: A systematic review. JAMA Neurology, 78, 864\u2013873.","journal-title":"JAMA Neurology"}],"container-title":["Neurological Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-022-00218-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42466-022-00218-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-022-00218-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,6]],"date-time":"2024-10-06T22:04:19Z","timestamp":1728252259000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurolrespract.biomedcentral.com\/articles\/10.1186\/s42466-022-00218-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,31]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["218"],"URL":"https:\/\/doi.org\/10.1186\/s42466-022-00218-4","relation":{},"ISSN":["2524-3489"],"issn-type":[{"value":"2524-3489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,31]]},"assertion":[{"value":"19 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Given by the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"54"}}